Valproate (Epilim▼) – Communications
The HPRA has issued communications to various healthcare professionals since the outcomes of the 2014 and 2017/2018 EU-wide reviews of Valproate (Epilim▼). These communications, listed below, include Direct Healthcare Professional Communications (DHPCs) and articles in the HPRA Drug Safety Newsletter.
These were distributed to healthcare professionals such as general practitioners, general hospital doctors, medical specialists including neurologists, gynaecologists/obstetricians, psychiatrists, pharmacists (both community and hospital), specialist epilepsy nurses and family planning clinics), healthcare professional regulatory bodies, and patient organisations.
In addition, the HPRA provided reminder articles which were published in MIMS (Ireland) and the Irish Medicines Formulary (IMF). All of these communications were published on the HPRA website and are linked below.